Back to search results

Brain Tumor Metabolism Study with 13C-glucose

This study is investigating how brain tumors use energy (their metabolism) in patients who are having surgery to remove a brain mass. Researchers will give you a special type of sugar called 13C-glucose (a non-radioactive, naturally occurring form of glucose) before your surgery. After your tumor is removed, they will analyze it to understand its metabolic fingerprint and compare this to what the tumor looks like under a microscope. This study aims to enroll 40 participants. You may be able to join if you are 18 or older, male or female, and have imaging that suggests a brain tumor or a biopsy showing a tumor that needs to be surgically removed. The study's success will be measured by how well the tumor's metabolic fingerprint matches its diagnosis after surgery, with follow-up between 1 and 14 days.

Study design
This is an interventional study, meaning you will receive a specific intervention (13C-glucose infusion). The study plans to enroll 40 participants.
What's involved
You will receive an infusion of 13C-glucose before your planned brain tumor surgery. You will also undergo several preoperative brain imaging studies, including a 3T MRI, 7T MRI, and a brain 18FDG-PET scan, within 7-14 days of your surgery.
Compensation
Not stated in the trial record.
Follow-up
Your tumor's metabolic phenotype will be correlated to clinical endpoints at the end of a follow-up period, which is between 1 and 14 days after surgery.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT01668082

An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

Recruiting
NAAges 18+InterventionalDiagnostic
University of Texas Southwestern Medical Center
~40 participants
Updated 2026-05-19 on ClinicalTrials.gov
What's tested:surgical resection of a brain tumor

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
metabolic phenotype correlation to clinical endpoints
Measured over at end of follow-up period- between days 1-14

Conditions

Brain Mass

Explore related trials

Brain Neoplasm

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Elizabeth Maher, MD, PhD · PRINCIPAL_INVESTIGATOR · University of Texas

Who to contact

Elizabeth Maher, MD, PhD
214-648-7097
Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or female, any age and any racial or ethnic group
Spanish-speaking patients will be eligible
Pre-operative brain MR imaging suggestive of a brain tumor or pre-operative imaging showing a tumor or biopsy of a tumor mass prior to planned resection of the mass
Patient able and willing to provide informed consent or Legal parent or guardian willing and able to provide informed consent for patient under age 18.
Karnofsky Performance status \> 70%
Negative serum pregnancy test or child bearing potential terminated by surgery, radiation, menopause or current use of two approved methods of birth control

Exclusion

Patient or legal parent/guardian unable to provide informed consent
Karnofsky Performance status \< 70%
Patients who are claustrophobic or have other contraindications to MRI, such as impanted pacemaker device vascular clips, surgical clips, prosthetic valves, pacemakers, otologic implants
NYHA class III and IV congestive heart failure
Psychiatric or addictive disorders that preclude obtaining informed consent
Unstable angina
Pregnant or lactating women
Women of childbearing potential who refuse a pregnancy test (performed during screening)

What this trial measures

  • metabolic phenotype correlation to clinical endpointsat end of follow-up period- between days 1-14

    To correlate the metabolic phenotype obtained from histopathological diagnosis with the clinical endpoints of time to tumor progression and overall survival during the 5 years of patient follow-up